RGC vs PBH
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
RGC · Regencell Bioscience$4.18 ▼ 4.13%
PBH · Prestige Consumer Healthcare$49.63 ▲ 0.06%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- RGC -64.2%
- PBH -13.6%
Head to head
| Metric | RGC | PBH |
|---|---|---|
| Price | $4.18 | $49.63 |
| Change today | ▼ 4.13% | ▲ 0.06% |
| Market cap | $2.07B | $2.35B |
| Return, 3 months | -21.0% | -4.6% |
| Return, year to date | -80.1% | -19.5% |
| Return, 1 year | -66.5% | -16.5% |
| P/E (TTM) | – | 15.3 |
| P/B | 154.8 | 1.2 |
| P/E percentile vs own 5y | 41st | 39th |
| Dividend yield | – | – |
| Revenue growth (YoY, latest qtr) | +6.0% | +22.7% |
| Net profit growth (YoY) | -46.4% | -40.1% |
| Gross margin | 62.4% | 52.5% |
| Operating margin | 10.5% | 25.0% |
| Net margin | 3.4% | 13.3% |
| Return on equity | -128.5% | 8.2% |
| Analyst target vs. price | – | +41.0% |
| Analyst buy share | – | 100% |
| RSI (14) | 30 | 56 |
| 30-day volatility | 127.8% | 67.1% |
| Max drawdown, 1 year | -92.1% | -38.8% |
| Trend read | Strong downtrend | Leaning bullish |
| Analyst consensus | – | Buy |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- PBH is the largest of the group by market value.
- PBH has returned the most over the past year.
- PBH is growing revenue fastest.
- PBH keeps the most profit per dollar of sales.
- PBH has been the calmest stock over the last 30 days.